Home › Therapeutic areas › Oncology › Multiple Myeloma
Multiple Myeloma (12 companies)
Companies with an active program in Multiple Myeloma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $341M | 12 |
| CCCC | C4 Therapeutics | Oncology | 1 | Phase 2 | $407M | 2 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | $230M | 4 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $11.8M | 6 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $224M | 10 |
| FHTX | Foghorn Therapeutics | Oncology | 1 | Preclinical | $111M | 4 |
| LEGN | Legend Biotech | Oncology Rare | 5 | Approved | $4.55B | 17 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $914M | 5 |
| SANA | Sana Biotechnology | MetabolicOncology | 1 | Phase 1 | $710M | 4 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $1.70B | 9 |
| TLX | Telix Pharmaceuticals | Oncology | 1 | Approved | $3.27B | 25 |
No companies match.